DOCSLIB.ORG

Clinical Practice Guidelines for the Prevention and Treatment of EGFR Inhibitor-Associated Dermatologic Toxicities

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Practice Guidelines for the Prevention and Treatment of EGFR Inhibitor-Associated Dermatologic Toxicities Support Care Cancer (2011) 19:1079–1095 DOI 10.1007/s00520-011-1197-6 REVIEW ARTICLE Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities Mario E. Lacouture & Milan J. Anadkat & René-Jean Bensadoun & Jane Bryce & Alexandre Chan & Joel B. Epstein & Beth Eaby-Sandy & Barbara A. Murphy & MASCC Skin Toxicity Study Group Received: 14 February 2011 /Accepted: 17 May 2011 /Published online: 1 June 2011 # Springer-Verlag 2011 Abstract Results Prophylactic and reactive recommendations for pap- Background Epidermal growth factor receptor inhibitors ulopustular (acneiform) rash, hair changes, radiation derma- (EGFRI) produce various dermatologic side effects in the titis, pruritus, mucositis, xerosis/fissures, and paronychia are majority of patients, and guidelines are crucial for the presented, as well as general dermatologic recommendations prevention and treatment of these untoward events. The when possible. purpose of this panel was to develop evidence-based recom- Conclusion Prevention and management of EGFRI-related mendations for EGFRI-associated dermatologic toxicities. dermatologic toxicities is critical to maintain patients’ Methods A multinational, interdisciplinary panel of experts in health-related quality of life and dose intensity of antineo- supportive care in cancer reviewed pertinent studies using plastic regimens. More rigorous investigation of these established criteria in order to develop first-generation recom- toxicities is warranted to improve preventive and treatment mendations for EGFRI-associated dermatologic toxicities. strategies. The MASCC Skin Toxicity Study Group is composed of Andrei Barasch, Camilla Beder, Christine B. Boers-Doets, Tracey Doherty, Judith E. Raber-Durlacher, Dion Forstner, Seppo Langer, Judith Lees, and Dan Mellor. Electronic supplementary material The online version of this article (doi:10.1007/s00520-011-1197-6) contains supplementary material, which is available to authorized users. M. E. Lacouture (*) A. Chan Dermatology Service, Department of Medicine, National University of Singapore, Memorial Sloan–Kettering Cancer Center, Singapore, Singapore Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd Street, New York, NY 10022, USA e-mail: [email protected] J. B. Epstein University of Illinois at Chicago, M. J. Anadkat Chicago, IL, USA Washington University School of Medicine, St. Louis, MO, USA B. Eaby-Sandy R.-J. Bensadoun University of Pennsylvania, Centre Hospitalier Universitaire de Poitiers, Philadelphia, PA, USA Poitiers Cedex, France J. Bryce B. A. Murphy Istituto Nazionale dei Tumori, Vanderbilt University Medical Center, Naples, Italy Nashville, TN, USA 1080 Support Care Cancer (2011) 19:1079–1095 Keywords Rash . Xerosis . Paronychia . Pruritus . Radiation ically similar dermatologic conditions were analyzed and dermatitis . Mucositis . EGFR inhibitors . Recommendations reported. Background Methods Overexpression of the epidermal growth factor receptor Participants (EGFR) is strongly associated with cancer development and progression of a number of malignancies. EGFR inhibitors The Multinational Association for Supportive Care in Cancer (EGFRI) are targeted agents used for treating lung (MASCC) Skin Toxicity Study Group assembled an interna- (erlotinib), pancreatic (erlotinib in combination with gem- tional, interdisciplinary group of experts in dermatology, citabine), breast (lapatinib in combination with capecitabine medical and supportive oncology, health-related quality of or anastrozole), head and neck (cetuximab in combination life (HQOL), and pharmacovigilance. Topic review commit- with radiotherapy), and colorectal cancers (cetuximab, tees were formed according to expertise to review the panitumumab) [1]. EGFRI may be used as first-line through literature and develop guidelines for the following dermato- third-line treatments, alone or in combination with other logic toxicities: papulopustular (acneiform) rash, hair changes, agents in the aforementioned cancers. radiation dermatitis, pruritus, mucositis, xerosis/fissures, and Commonly experienced dermatologic side effects in- paronychia. clude papulopustular (acneiform) rash, hair changes, radi- ation dermatitis enhancement, pruritus, mucositis, xerosis/ Recommendation development fissures, and paronychia. Incidences of these side effects are frequent and range from 36% for mucositis to 80% for Each review committee consisted of three members with a papulopustular (acneiform) rash. Clinical presentation, primary reviewer to present the findings of the committee incidence, impact on quality of life and cost, effect on to the Skin Toxicity Study Group. Literature reviews were EGFRI dosing, and risk factors for these toxicities have performed via databases such as Ovid MEDLINE (National been described elsewhere [1]. When severe, dermatologic Library of Medicine, Bethesda, MD, USA) and EMBASE toxicities may to lead to dose modification or discontinu- (Elsevier B.V. Amsterdam, The Netherlands). Published ation by 36% and 72% of health care providers, respec- literature as of November 2010 was included and each tively [2]. Although the side effect profile may be primarily committee reviewed between 17 and 35 papers to formulate dermatologic, toxicities result in significant physical and the recommended guidelines. Randomized clinical trials emotional discomfort, thus it is critical to maximize were considered the best source, and considerations for supportive measures. recommendations included Level of Evidence and Grade of Although most patients receiving EGFRIs experience Recommendation (Tables 1 and 2)[3]. In the absence of these toxicities, few controlled studies have been conducted experimental evidence, pertinent studies and case reports to determine the best practices for their management. were presented in conjunction with expert opinion derived Instead, much of the literature contains prevention and from clinical practice. Recommendations were developed treatment recommendations based on case reports or studies based on the presented findings and panel consensus. When with small samples sizes and nonrandomized patient available, data were extrapolated from other dermatologic allocation. In addition, available reports are beset with conditions with similar clinical or pathologic characteristics methodological issues including failure to adequately (xerosis, alopecia and hirsutism, pruritus, paronychia, and describe assessment tools or frequency, lack of validated radiation dermatitis). tools for the assessment of dermatologic toxicities, and passive data collection. Given that these agents are relatively devoid of systemic and hematopoietic toxicities and have shown benefit in a variety of solid tumors, further Table 1 Levels of evidence [3] large-scale studies to define best supportive care are necessary but are unlikely to become available in the Level I evidence is reserved for meta-analyses of randomized controlled trials or randomized trials with high power. foreseeable future. The purpose of this article is to provide Level II evidence includes randomized trials with lower power. comprehensive supportive care prevention and treatment Level III evidence includes nonrandomized trials, such as cohort or recommendations for EGFRI-induced dermatologic toxic- case-controlled series. ities based on the pertinent literature currently available. In Level IV evidence includes descriptive and case studies. cases where randomized clinical trials specific to EGFRI Level V evidence includes case reports and clinical examples. toxicities were not available, trials investigating phenotyp- Support Care Cancer (2011) 19:1079–1095 1081 Table 2 Recommendation grades [3] with moisturizer, sunscreen, and doxycycline 100 mg bid for Grade A is reserved for level I evidence or consistent findings from the first 6 weeks is recommended based on randomized data. multiple studies of levels II, III, or IV evidence. Another study revealed that prophylactic minocycline Grade B is for levels II, III, or IV evidence with generally consistent 100 mg daily is an effective agent in reducing the number findings. of lesions during the first 8 weeks. Doxycycline appears to Grade C is similar to grade B but with inconsistencies. have a more favorable safety profile, especially in patients Grade D implies little or no evidence. with renal dysfunction, whereas minocycline is less photo- sensitizing, thus preferable in geographic or seasonal locations with a high UV index. Results and recommendations Reactive use of medium- to high-potency topical cortico- steroids is recommended based on studies showing in vitro Papulopustular (acneiform) rash release of inflammatory chemokines after EGFRI therapy. Vitamin K3 (menadione) is currently being investigated, During the first weeks to months of EGFRI therapy, a but published reports on vitamin K1 are based on studies papulopustular (acneiform) rash is the most clinically without control groups [13, 14]. Similarly, studies investi- significant dermatologic toxicity. The rash usually develops gating isotretinoin for the treatment of EGFRI-induced rash in cosmetically sensitive areas, and it affects the majority of have not included control groups, but consistent reports of treated patients. Pruritic and tender erythematous papules isotretinoin at doses lower than those used for acne support and pustules develop in skin (Fig. 1a–c) with a high density the recommendation of their use when other measures have of sebaceous glands (scalp, face,
Load more

Recommended publications
  • Assessment of Overall Survival, Quality of Life, And
    Supplementary Online Content Salas-Vega S, Iliopoulos O, Mossialos E. Assesment of overall survival, quality of life, and safety benefits associated with new cancer medicines [published online December 29, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2016.4166 eTable 1. Therapeutic profile of all cancer medicines approved by the FDA between 2003- 2013 eTable 2. Regulatory evidence in support of classification of drug clinical benefits eFigure 1. Number of cancer drugs that were evaluated by all three HTA agencies, sorted by magnitude of clinical benefits eTable 3. Interagency agreement–Krippendorff’s alpha coefficients eMethods This supplementary material has been provided by the authors to give readers additional information about their work. Online-Only Supplement © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/25/2021 Clinical value of cancer medicines Contents eExhibits ......................................................................................................................................................... 3 eTable 1. Therapeutic profile of all cancer medicines approved by the FDA between 2003- 2013 (Summary of eTable 2) ................................................................................................................... 3 eTable 2. Regulatory evidence in support of classification of drug clinical benefits ....................... 6 eFigure 1. Number of cancer drugs that were evaluated by all three HTA agencies, sorted by magnitude of clinical benefits
    [Show full text]
  • Endocrinology 12 Michel Faure, Evelyne Drapier-Faure
    Chapter 12 Endocrinology 12 Michel Faure, Evelyne Drapier-Faure Key points 12.1 Introduction Q HS does not generally appear to be In 1986 Mortimer et al. [14] reported that hi- associated with signs of hyperan- dradenitis suppurativa (HS) responded to treat- drogenism ment with the potent antiandrogen cyproterone acetate. They suggested that the disease could Q Sex hormones may affect the course of be androgen-dependent [8]. This hypothesis HS indirectly through, for example, was also upheld by occasional reports of women their effects on inflammation with HS under antiandrogen therapy [18]. Actu- ally, the androgen dependence of HS (similarly Q The role of end-organ sensitivity to acne) is only poorly substantiated. cannot be excluded at the time of writing 12.2 Hyperandrogenism and the Skin Q The prevalence of polycystic ovary syndrome in HS has not been system- Androgen-dependent disorders encompass a atically investigated broad spectrum of overlapping entities that may be related in women to the clinical consequenc- es of the effects of androgens on target tissues and of associated endocrine and metabolic dys- functions, when present. #ONTENTS 12.1 Introduction ...........................95 12.2.1 Androgenization 12.2 Hyperandrogenism and the Skin .........95 12.2.1 Androgenization .......................95 One of the less sex-specific effects of androgens 12.2.2 Androgen Metabolism ..................96 12.2.3 Causes of Hyperandrogenism ...........96 is that on the skin and its appendages, and in particular their action on the pilosebaceous 12.3 Lack of Association between HS unit. Hirsutism is the major symptom of hyper- and Endocrinopathies ..................97 androgenism in women.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Cutaneous Adverse Effects of Biologic Medications
    REVIEW CME MOC Selena R. Pasadyn, BA Daniel Knabel, MD Anthony P. Fernandez, MD, PhD Christine B. Warren, MD, MS Cleveland Clinic Lerner College Department of Pathology Co-Medical Director of Continuing Medical Education; Department of Dermatology, Cleveland Clinic; of Medicine of Case Western and Department of Dermatology, W.D. Steck Chair of Clinical Dermatology; Director of Clinical Assistant Professor, Cleveland Clinic Reserve University, Cleveland, OH Cleveland Clinic Medical and Inpatient Dermatology; Departments of Lerner College of Medicine of Case Western Dermatology and Pathology, Cleveland Clinic; Assistant Reserve University, Cleveland, OH Clinical Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH Cutaneous adverse effects of biologic medications ABSTRACT iologic therapy encompasses an expo- B nentially expanding arena of medicine. Biologic therapies have become widely used but often As the name implies, biologic therapies are de- cause cutaneous adverse effects. The authors discuss the rived from living organisms and consist largely cutaneous adverse effects of tumor necrosis factor (TNF) of proteins, sugars, and nucleic acids. A clas- alpha inhibitors, epidermal growth factor receptor (EGFR) sic example of an early biologic medication is inhibitors, small-molecule tyrosine kinase inhibitors insulin. These therapies have revolutionized (TKIs), and cell surface-targeted monoclonal antibodies, medicine and offer targeted therapy for an including how to manage these reactions
    [Show full text]
  • Hair Depilation for Hirsutism
    Hair Depilation for Hirsutism Policy NHS NWL CCGs will fund facial hair depilation only when the following criteria are met: Facial There is an existing endocrine medical condition and severe facial hirsutism Ferriman Gallwey Score of 3 or more per area requested Medical treatments such as hormone suppression therapy has been tried for at least one year and failed. Patients with a BMI>30 should be in a weight reduction programme and should at least 5% of their body weight. Peri Anal Removal of excess hairs in the peri anal area will only be funded as part of treatment for pilonidal sinuses. Other Area Have undergone reconstructive surgery leading to abnormally located hair- bearing skin Laser treatment for excess hair (hirsutism) will only be funded for 6 treatment sessions and only at NHS commissioned services. Hair depilation for sites other than the above is not routinely funded and may be available via the IFR route under exceptional circumstances. These polices have been approved by the eight Clinical Commissioning Groups in North West London (NHS Brent CCG, NHS Central London CCG, NHS Ealing CCG, NHS Hammersmith and Fulham CCG, NHS Harrow CCG, NHS Hillingdon CCG, NHS Hounslow CCG and NHS West London CCG). Background Hirsutism is excessive hair growth in women in areas of the body where only to develop coarse hair, primarily on the face and neck area.1 Unwanted and excessive hair growth is a common problem and considerable amounts of time and money are spent on hair removal. It affects about 5-10% of women, and is often quoted as a cause of emotional distress.
    [Show full text]
  • Isotretinoin Induced Periungal Pyogenic Granuloma Resolution with Combination Therapy Jonathan G
    Isotretinoin Induced Periungal Pyogenic Granuloma Resolution with Combination Therapy Jonathan G. Bellew, DO, PGY3; Chad Taylor, DO; Jaldeep Daulat, DO; Vernon T. Mackey, DO Advanced Desert Dermatology & Mohave Centers for Dermatology and Plastic Surgery, Peoria, AZ & Las Vegas, NV Abstract Management & Clinical Course Discussion Conclusion Pyogenic granulomas are vascular hyperplasias presenting At the time of the periungal eruption on the distal fingernails, Excess granulation tissue and pyogenic granulomas have It has been reported that the resolution of excess as red papules, polyps, or nodules on the gingiva, fingers, the patient was undergoing isotretinoin therapy for severe been described in both previous acne scars and periungal granulation tissue secondary to systemic retinoid therapy lips, face and tongue of children and young adults. Most nodulocystic acne with significant scarring. He was in his locations.4 Literature review illustrates rare reports of this occurs on withdrawal of isotretinoin.7 Unfortunately for our commonly they are associated with trauma, but systemic fifth month of isotretinoin therapy with a cumulative dose of adverse event. In addition, the mechanism by which patient, discontinuation of isotretinoin and prevention of retinoids have rarely been implicated as a causative factor 140 mg/kg. He began isotretinoin therapy at a dose of 40 retinoids cause excess granulation tissue of the skin is not secondary infection in areas of excess granulation tissue in their appearance. mg daily (0.52 mg/kg/day) for the first month and his dose well known. According to the available literature, a course was insufficient in resolving these lesions. To date, there is We present a case of eruptive pyogenic granulomas of the later increased to 80 mg daily (1.04 mg/kg/day).
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Metformin for the Treatment of Hidradenitis Suppurativa: a Little Help Along the Way
    DOI: 10.1111/j.1468-3083.2012.04668.x JEADV ORIGINAL ARTICLE Metformin for the treatment of hidradenitis suppurativa: a little help along the way R. Verdolini,† N. Clayton,‡,* A. Smith,‡ N. Alwash,† B. Mannello§ †Department of Dermatology, Princess Alexandra Hospital NHS trust, Harlow, Essex, and ‡Department of Dermatology, The Royal London Hospital, London, UK §Mannello Statistics, Via Rodi, Ancona, Italy *Correspondence: N. Clayton. E-mail: [email protected]; [email protected] Abstract Background Despite recent insights into its aetiology, hidradenitis suppurativa (HS) remains an intractable and debilitating condition for its sufferers, affecting an estimated 2% of the population. It is characterized by chronic, relapsing abscesses, with accompanying fistula formation within the apocrine glandbearing skin, such as the axillae, ano-genital areas and breasts. Standard treatments remain ineffectual and the disease often runs a chronic relapsing course associated with significant psychosocial trauma for its sufferers. Objective To evaluate the clinical efficacy of Metformin in treating cases of HS which have not responded to standard therapies. Methods Twenty-five patients were treated with Metformin over a period of 24 weeks. Clinical severity of the disease was assessed at time 0, then after 12 weeks and finally after 24 weeks. Results were evaluated using Sartorius and DLQI scores. Results Eighteen patients clinically improved with a significant average reduction in their Sartorius score of 12.7 and number of monthly work days lost reduced from 1.5 to 0.4. Dermatology life quality index (DLQI) also showed a significant improvement in 16 cases, with a drop in DLQI score of 7.6.
    [Show full text]
  • Palifermin (Kepivance™) in the Treatment of Mucositis
    Session V • From cell biology to cell therapy Palifermin (Kepivance™) in the treatment of mucositis [haematologica reports] 2005;1(8):41-45 EMMANOUILIDES C n patients undergoing high dose chemo- factor (KGF) is a 28 kD member of the therapy and hematopoietic stem cell fibroblast growth factor family with epithe- Associate Profesor transplant, oral mucositis (OM) is one of lial cell proliferative properties.26 Palifermin of Medicine, UCLA, I Division Haematology-Oncology, the most debilitating and annoying side (Kepivance™) is a truncated, recombinant Thessaloniki, Greece effects. This complication results from form of human keratinocyte growth factor cytotoxic injury to the epithelial lining of (rHuKGF) that has been approved in the the oropharyngeal mucosa, although USA in 2004 to decrease the incidence and lesions of the whole gastrointestinal tract duration of severe OM in patients with also occur.1 The severity of OM varies from hematologic malignancies receiving myelo- erythema and edema accompanied by mild toxic therapy requiring HSCT support. Pal- soreness to full mucosal thickness ulcera- ifermin (recombinant human keratinocyte tions penetrating into the submucosa, growth factor) is an N-terminal, truncated often resulting in severe pain requiring version of endogenous keratinocyte growth narcotic analgesia and impaired swallow- factor with biologic activity similar to that ing, prolonged hospitalization, and of the native protein, but with increased increased risks for infections and poten- stability 26 In animal models of chemother- tially life-threatening sequelae.2,3 Between apy, radiotherapy, and hematopoietic stem- 40% to 80% of cancer patients undergo- cell transplantation27,28 palifermin protected ing intensive treatment regimens requiring several types of epithelial tissues.
    [Show full text]
  • Ingrown Nail/Paronychia Referral Guide: Podiatry Referral Page 1 of 1 Diagnosis/Definition
    Ingrown Nail/Paronychia Referral Guide: Podiatry Referral Page 1 of 1 Diagnosis/Definition: Redness, warmth, tenderness and exudate coming from the areas adjacent to the nail plate. Initial Diagnosis and Management: History and physical examination. In chronic infection appropriate radiographic (foot or toe series to rule out distal phalanx osteomyelitis) and laboratory evaluation (CBC and ESR). Ongoing Management and Objectives: Primary care should consist of Epsom salt soaks, or soapy water, and antibiotics for ten days. If Epsom salt soaks and antibiotics are ineffective, the primary care provider has the following options: Reevaluate and refer to podiatry. Perform temporary avulsion/I&D. Perform permanent avulsion followed by chemical cautery (89% Phenol or 10% NaOH application – 3 applications maintained for 30 second intervals, alcohol dilution between each application). Aftercare for all of the above is continued soaks, daily tip cleaning and bandage application. Indications for Specialty Care Referral: After the reevaluation at the end of the antibiotic period the primary care provider can refer the patient to Podiatry for avulsion/ surgical care if they do not feel comfortable performing the procedure themselves. The patient should be given a prescription for antibiotics renewal and orders to continue soaks until avulsion can be performed. Test(s) to Prepare for Consult: Test(s) Consultant May Need To Do: Criteria for Return to Primary Care: After completion of the surgical procedure, patients will be returned to the primary care provider for follow-up. Revision History: Created Revised Disclaimer: Adherence to these guidelines will not ensure successful treatment in every situation. Further, these guidelines should not be considered inclusive of all accepted methods of care or exclusive of other methods of care reasonably directed to obtaining the same results.
    [Show full text]
  • Onychomycosis/ (Suspected) Fungal Nail and Skin Protocol
    Onychomycosis/ (suspected) Fungal Nail and Skin Protocol Please check the boxes of the evaluation questions, actions and dispensing items you wish to include in your customized protocol. If additional or alternative products or services are provided, please include when making your selections. If you wish to include the condition description please also check the box. Description of Condition: Onychomycosis is a common nail condition. It is a fungal infection of the nail that differs from bacterial infections (often referred to as paronychia infections). It is very common for a patient to present with onychomycosis without a true paronychia infection. It is also very common for a patient with a paronychia infection to have secondary onychomycosis. Factors that can cause onychomycosis include: (1) environment: dark, closed, and damp like the conventional shoe, (2) trauma: blunt or repetitive, (3) heredity, (4) compromised immune system, (5) carbohydrate-rich diet, (6) vitamin deficiency or thyroid issues, (7) poor circulation or PVD, (8) poor-fitting shoe gear, (9) pedicures received in places with unsanitary conditions. Nails that are acute or in the early stages of infection may simply have some white spots or a white linear line. Chronic nail conditions may appear thickened, discolored, brittle or hardened (to the point that the patient is unable to trim the nails on their own). The nails may be painful to touch or with closed shoe gear or the nail condition may be purely cosmetic and not painful at all. *Ask patient to remove nail
    [Show full text]
  • Also Called Androgenetic Alopecia) Is a Common Type of Hereditary Hair Thinning
    750 West Broadway Suite 905 - Vancouver BC V5Z 1H8 Phone: 604.283.9299 Fax: 604.648.9003 Email: [email protected] Web: www.donovanmedical.com Female Pattern Hair Loss Female pattern hair loss (also called androgenetic alopecia) is a common type of hereditary hair thinning. Although hair may become quite thin, women do not become bald as in men. Hair thinning starts as early as the teenage years, but usually in the twenties and thirties and is usually fully expressed by the age of 40. How can one recognize female pattern hair loss? § Typically, a female in her teens, twenties or thirties gradually becomes aware that she has less hair on the top of her head than previously. § She may notice that her scalp has become slightly visible now and it takes more effort to style the hair to hide the thinning. § The size of the ponytail becomes smaller in diameter. § While all this is happening, she may also notice that her hair becomes greasy and stringy more quickly and she shampoos more often to keep the hair looking fuller volume. § One of the earliest signs of androgenetic alopecia is widening of the ‘central part’ (down the middle of the scalp). The spacing between hairs gradually increases. The thinning gradually becomes diffuse and may be present all over the scalp but is usually most pronounced over the top and sides of the head. § There is much variation in the diameter and length of hairs – some and thick and long while others are fine and short. This variation in size represents the gradual miniaturization of hair follicles- they become smaller and smaller.
    [Show full text]